Observing quality of life in prostate cancer patients after biopsy and surgery
Official title: Observational Study of Patients Who Underwent Diagnostic Investigation (Prostate Biopsy) and/or Radical Prostatectomy Surgery.
Run by IRCCS San Raffaele · NCT06397755 · Data updated 2026-11-12
This study looks at how the quality of life changes for men with prostate cancer after they have a biopsy or surgery, by collecting their experiences through questionnaires over many years.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Men only |
| Enrollment | 20000 (estimated) |
| Sponsor | IRCCS San Raffaele Academic / other |
| Locations | 1 site (Milan) |
| Status | Recruiting |
| Started | January 8, 2015 |
| Main results expected | January 8, 2065 |
| Study ends | January 8, 2065 |
| Registry record updated | May 3, 2024 |
| Trial ID | NCT06397755 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adult patients over 18 years old with a suspicious prostate disease who are undergoing prostate biopsy and/or radical prostatectomy.
✕Probably not a fit
Patients under 18 years old or those with mental or physical disabilities that prevent them from participating in the study may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study collects data on the quality of life and disease status of patients who have undergone prostate biopsy and/or radical prostatectomy. It involves both prospective and retrospective data collection, with patients followed for up to 50 years post-surgery. Participants will complete questionnaires before and after their surgical procedures to assess their experiences and outcomes. The data will be meticulously managed in accordance with strict guidelines to ensure patient privacy and adherence to good clinical practices.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the long-term quality of life for prostate cancer patients, informing future treatment and care strategies.
How similar studies have gone: While observational studies on quality of life in cancer patients are common, the long-term follow-up aspect of this study may provide novel insights into patient outcomes.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with a suspicious prostate disease who underwent prostate biopsy and/or radical prostatectomy; * Adult patients \> 18 years * Ability to read and sign the informed consent Exclusion Criteria: * Patients \< 18 years * mental or physical disability that may prevent the patient from satisfying the requirements of the protocol * Inability to read and sign the informed consent
Where it's running
-
IRCCS Ospedale San Raffaele
Milan, Italy Recruiting
Study contacts
- Study coordinator: Andrea Salonia
- Email: salonia.andrea@hsr.it
- Phone: +39 0226435661
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519
This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.
-
PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer
This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.
-
Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer
This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.
-
Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer
This observational study tests whether salvage HDR brachytherapy can help men with locally recurrent prostate cancer after initial radiotherapy, using advanced imaging and biopsy to guide treatment.
-
Multi-peptide Vaccination and PSMAxCD3 Antibody Therapy for Prostate Cancer with Biochemical Recurrence
This phase 2 trial tests whether a PSMA-targeted bispecific antibody (CC-1), a prostate cancer peptide vaccine (VAC-XS15-PC01), or both can be given safely and help control biochemical recurrence after local therapy in men with prostate cancer.
-
Lutetium-177 Ludotadipep for advanced prostate cancer
This study tests whether adding Lu-177 Ludotadipep to standard care helps men with metastatic castration-resistant prostate cancer live longer without their disease getting worse.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.